A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy Correspondence
| Authors: | Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; Chung, D. J.; Lahoud, O. B.; Hassoun, H.; Lesokhin, A. M.; Landau, H. J.; Shah, G.; Scordo, M.; Giralt, S. A.; Usmani, S. Z.; Roshal, M.; Landgren, O.; Mailankody, S. |
| Title: | A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy |
| Keywords: | adult; clinical article; human tissue; treatment response; aged; survival analysis; overall survival; lenalidomide; drug efficacy; treatment duration; cancer patient; flow cytometry; positron emission tomography; follow up; antineoplastic agent; letter; progression free survival; bortezomib; multiple cycle treatment; multiple myeloma; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; cohort analysis; dexamethasone; melphalan; monoclonal antibody; antibodies, monoclonal; bone marrow biopsy; minimal residual disease; neoplasm, residual; fluorodeoxyglucose f 18; therapy effect; autologous hematopoietic stem cell transplantation; induction chemotherapy; carfilzomib; short course therapy; maintenance chemotherapy; humans; human; male; female; median survival time; monoclonal antibody therapy; daratumumab |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 63 |
| Issue: | 14 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2022-01-01 |
| Start Page: | 3488 |
| End Page: | 3492 |
| Language: | English |
| DOI: | 10.1080/10428194.2022.2131417 |
| PUBMED: | 36282633 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding author is MSK author Sham Mailankody -- Export Date: 1 March 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
